{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:35Z","timestamp":1790222855470,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1735,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Acute hepatitis C continues to be a concern in men who have sex with men (MSM), and its optimal management has yet to be established. In this study, the clinical, biological, and therapeutic data of 53 human immunode\ufb01ciency virus (HIV)-infected MSM included in a multicenter prospective study on acute hepatitis C in 2006-2007 were retrospectively col-lected and analyzed. The mean hepatitis C virus (HCV) viral load at diagnosis was 5.8 61.1 log\n                      <jats:sub>10<\/jats:sub>\n                      IU\/mL (genotype 4, n 5 28; genotype 1, n 5 14, genotype 3, n 5 7). The cumu-lative rates of spontaneous HCV clearance were 11.0% and 16.5% 3 and 6 months after di-agnosis, respectively. Forty patients were treated, 38 of whom received pegylated interferon and ribavirin. The mean duration of HCV therapy was 39 6 17 weeks (24 6 4 weeks in 14 cases). On treatment, 18\/36 (50.0%; 95% con\ufb01dence interval 34.3-65.7) patients had undetectable HCV RNA at week 4 (RVR), and 32\/39 (82.1%; 95 con\ufb01dence interval 70.0-94.1) achieved sustained virological response (SVR). SVR did not correlate with pretreat-ment parameters, including HCV genotype, but correlated with RVR (predictive positive value of 94.4%) and with effective duration of HCV therapy (64.3% for 24 6 4 weeks ver-sus 92.0% for longer treatment;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      5 0.03).\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                      The low rate of spontaneous clear-ance and the high SVR rates argue for early HCV therapy following diagnosis of acute hepatitis C in HIV-infected MSM. Pegylated interferon and ribavirin seem to be the best option. The duration of treatment should be modulated according to RVR, with a 24-week course for patients presenting RVR and a 48-week course for those who do not, irre-spectively of HCV genotype. (HEPATOLOGY 2010;52:1915-1921)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23959","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T00:00:32Z","timestamp":1283904032000},"page":"1915-1921","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Treatment of Acute Hepatitis C in Human Immunode\ufb01ciency Virus\u2013Infected Patients"],"prefix":"10.1097","volume":"52","author":[{"given":"Lionel","family":"Piroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Binquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Auperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ste\u00b4phanie","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Delarocque-Astagneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20251124","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2807\/esm.10.05.00535-en","article-title":"Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004","volume":"10","author":"Gambotti","year":"2005","journal-title":"Euro Surveill"},{"key":"R2-8-20251124","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1086\/587843","article-title":"Impact of HIV on host-virus interactions during early hepatitis C virus infection","volume":"197","author":"Danta","year":"2008","journal-title":"J Infect Dis"},{"key":"R3-8-20251124","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2006.00816.x","article-title":"Therapeutic issues in HIV\/HCV-coinfected patients","volume":"14","author":"Sulkowski","year":"2007","journal-title":"J Viral Hepat"},{"key":"R4-8-20251124","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2893.2009.01167.x","article-title":"Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis","volume":"17","author":"Corey","year":"2010","journal-title":"J Viral Hepat"},{"key":"R5-8-20251124","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R6-8-20251124","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/QAD.0b013e3282f5f4cf","article-title":"Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom","volume":"22","author":"Fox","year":"2008","journal-title":"AIDS"},{"key":"R7-8-20251124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1086\/600058","article-title":"Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection","volume":"49","author":"Vogel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R8-8-20251124","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/596770","article-title":"Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C","volume":"48","author":"Matthews","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R9-8-20251124","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","article-title":"Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men","volume":"136","author":"van","year":"2009","journal-title":"Gastroenterology"},{"key":"R10-8-20251124","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/01.aids.0000226956.02719.fd","article-title":"Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients","volume":"20","author":"Dominguez","year":"2006","journal-title":"AIDS"},{"key":"R11-8-20251124","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.aids.0000200541.40633.56","article-title":"Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy","volume":"20","author":"Serpaggi","year":"2006","journal-title":"AIDS"},{"key":"R12-8-20251124","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2893.2005.00580.x","article-title":"Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases","volume":"12","author":"Vogel","year":"2005","journal-title":"J Viral Hepat"},{"key":"R13-8-20251124","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350601100817","article-title":"Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals","volume":"11","author":"Vogel","year":"2006","journal-title":"Antivir Ther"},{"key":"R15-8-20251124","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3851\/IMP1501","article-title":"Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort","volume":"15","author":"Vogel","year":"2010","journal-title":"Antivir Ther"},{"key":"R16-8-20251124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.qai.0000174930.64145.a9","article-title":"Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin","volume":"40","author":"Gilleece","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-8-20251124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"R18-8-20251124","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1086\/598995","article-title":"Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients","volume":"48","author":"De","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R19-8-20251124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.qai.0000191281.77954.27","article-title":"Clinical presentation and course of acute hepatitis C infection in HIV-infected patients","volume":"41","author":"Luetkemeyer","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-8-20251124","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/605444","article-title":"Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection","volume":"200","author":"McGovern","year":"2009","journal-title":"J Infect Dis"},{"key":"R21-8-20251124","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatitis C virus-coinfected patients","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"key":"R22-8-20251124","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2893.2006.00802.x","article-title":"A short course of pegylated interferon-alpha in acute HCV hepatitis","volume":"14","author":"Calleri","year":"2007","journal-title":"J Viral Hepat"},{"key":"R23-8-20251124","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.21197","article-title":"Duration of peginterferon therapy in acute hepatitis C: a randomized trial","volume":"43","author":"Kamal","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R24-8-20251124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R25-8-20251124","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R26-8-20251124","first-page":"245","article-title":"Acute hepatitis C in HIV-positive individuals","volume":"10","author":"Low","year":"2008","journal-title":"AIDS Rev"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23959","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201012000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T19:00:18Z","timestamp":1764010818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201012000-00008"}},"subtitle":["The HEPAIG Study"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23959","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}